Osiris Therapeutics, Inc.  

(Public, NASDAQ:OSIR)   Watch this stock  
Find more results for OSIR
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 11.87 - 19.75
Open     -
Vol / Avg. 0.00/167,137.00
Mkt cap 625.90M
P/E 364.07
Div/yield     -
EPS 0.05
Shares 34.39M
Beta 1.29
Inst. own 39%
Aug 5, 2015
Q2 2015 Osiris Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 10, 2015
Osiris Therapeutics Inc Annual Shareholders Meeting - 1:30PM EDT - Add to calendar
May 8, 2015
Q1 2015 Osiris Therapeutics Inc Earnings Release
May 8, 2015
Q1 2015 Osiris Therapeutics Inc Earnings Call
Mar 25, 2015
Osiris Therapeutics Inc at Alliance for Regenerative Medicine RegenMed Investor Day
Mar 5, 2015
Q4 2014 Osiris Therapeutics Inc Earnings Release
Mar 5, 2015
Q4 2014 Osiris Therapeutics Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 6.56% -0.41%
Operating margin 8.77% 2.87%
EBITD margin - 4.44%
Return on average assets 5.53% -0.26%
Return on average equity 6.48% -0.30%
Employees 211 -
CDP Score - -


7015 Albert Einstein Drive
United States - Map
+1-443-5451800 (Phone)
+1-443-5451701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Osiris Therapeutics, Inc., is a stem cell company. The Company is focused on developing and marketing products to treat medical conditions in the wound, orthopedic, and sports medicine markets. As of December, 31, 2013, the Company markets and distributes Grafix and Ovation for acute and chronic wounds, Cartiform, a viable cartilage mess for cartilage repair and OvationOS, a viable bone matrix for bone growth. Grafix is a three-dimensional placental tissue matrix for use as a wound covering for application directly to acute and chronic wounds, including diabetic foot ulcers, venous leg ulcers, and burns. OvationOS, a viable bone matrix, is a product to be used for bone repair and regeneration. Cartiform is viable cartilage mesh designed for use in cartilage repair, such as marrow stimulation procedures.

Officers and directors

Peter Friedli Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Lode Debrabandere Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Philip R. Jacoby Jr. Chief Financial Officer, Treasurer, Corporate Secretary
Age: 62
Bio & Compensation  - Reuters
Gregory I. Law Vice President - Finance
Age: 48
Bio & Compensation  - Reuters
Frank D. Czworka Jr. Vice President, General Manager of Wound Care
Age: 45
Bio & Compensation  - Reuters
Adrian P. Mollo General Counsel
Age: 40
Bio & Compensation  - Reuters
Dwayne Montgomery General Manager Orthopedics and Sports Medicine
Age: 47
Bio & Compensation  - Reuters
Alla N. Danilkovitch Ph.D. Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Jonathan Mark Hopper Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Felix Gutzwiller M.D., Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters